Answer
Eculizumab specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and thereby preventing formation of the terminal complement complex C5b-9 while preserving early components of complement activation.
Sources for this answer
- Soliris 300 mg concentrate for solution for infusionAlexion Pharma UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 29Document updated
Sources checked